GlassScriptPhysician profile
Baron Hood
NPI 1851750582
$6,047.23
in general payments reported to CMS, 2019-2025
16 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $578 · 2023: $1,219 · 2024: $2,687 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,601 · Travel and Lodging: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.63 |
| Travel and Lodging | $746.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,948.56 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,343.14 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $374.17 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $347.61 | 2022-2024 | |
| Novo Nordisk INC | $265.24 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Emd Serono, INC. | $226.38 | 2022-2025 | Serostim |
| Theratechnologies INC. | $162.00 | 2022-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $144.52 | 2021-2023 | Symtuza |
| Verity Pharmaceuticals INC. | $66.08 | 2024-2025 | Tlando |
| Lilly USA, LLC | $63.19 | 2023-2024 | Mounjaro |
| Abbott Laboratories | $22.04 | 2025 | Freestyle Libre 3 |
| Csl Behring | $20.76 | 2023 | Hizentra |
| Dexcom, INC. | $16.76 | 2024 | Dexcom G6 Transmitter |
| Napo Pharmaceuticals INC | $16.69 | 2024 | Mytesi |
| Exact Sciences Corporation | $16.33 | 2025 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baron Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.